Diabetes
An Introduction to Diabetes
Diabetes is an enormous health burden worldwide, and the current epidemic of type 2 diabetes is of paramount concern. The most important recent advances in the management of type 1 diabetes have been immunotherapies, designed to delay disease onset and the development of fully automated artificial pancreas systems that integrate blood glucose monitoring and insulin delivery. In type 2 diabetes, the widespread use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors have facilitated optimal glycaemic control without increased risk of hypoglycaemia and weight gain. Emerging data from cardiovascular outcome trials have shown that these agents can reduce the risk of cardiovascular disease in high-risk individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
In this interview at EASD 2026, Katherine Tuttle discusses ACHIEVE-4 findings on the potential kidney-protective effects of orforglipron in people with type 2 diabetes and high cardiovascular risk, and the need for dedicated trials to confirm its long-term renal benefits.
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles exploring current developments in endocrine and metabolic care, from evolving diagnostic approaches to advances in treatment and the challenges ...
Diabetes mellitus, a multifactorial, chronic and progressive metabolic disorder primarily caused by elevated blood glucose levels, is a growing global health epidemic and a leading cause of adult mortality.1,2 By 2030, global diabetes prevalence is estimated to rise to 7,079 per 100,000 individuals, ...
In this EASD 2026 interview, Viral Shah discusses how continuous glucose monitoring could support earlier diabetes diagnosis, improve risk prediction and enable more personalized treatment and monitoring.
In this interview, Pablo Mora discusses phase 2b findings for zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist, including its effects on glycemic control and body weight in people with type 2 diabetes, and the potential of ongoing phase 3 trials.
Youth-onset type 2 diabetes is increasingly common in the USA, with incidence exceeding that of type 1 diabetes among 15–19-year-old adolescents and prevalence projected to increase by 673% by 2060.1,2 This growth is particularly worrisome due to the severity of youth-onset type 2 diabetes, which ...
New findings presented at EASD 2026 suggest that mild, lifelong reductions in insulin signaling may be associated with a more favorable metabolic profile, challenging the view that all forms of insulin resistance are detrimental to health.
From the relationship between glucose control and quality of life to the benefits of exercise and an unexpected finding on COVID-19 and type 1 diabetes, we highlight three studies presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.
Updated guidance presented at EASD 2026 emphasizes earlier use of organ-protective therapies, individualized weight management, and a broader approach to preventing diabetes-related complications.
Experts at EASD 2026 have welcomed a new European initiative encouraging routine health checks to identify cardiovascular and metabolic risk factors before complications develop.
EASD President Francesco Giorgino previews EASD 2026, discussing the key developments set to shape diabetes research and care, including incretin therapies, type 1 diabetes, AI and diabetes technology, personalized care, screening, and his priorities for EASD during his presidency.
Meet the endocrinologists shaping the future of the specialty. The touchENDOCRINOLOGY Future Leaders 2026 are rising stars nominated by the endocrinology community for their contributions to research, clinical practice and innovation. Discover the clinicians and researchers challenging convention, advancing care and driving progress across endocrinology.
In this touchENDOCRINOLOGY Future Leaders 2026 Q&A, Dr Simon Berry (Sheffield, UK) reflects on the experiences that led him into diabetes and endocrinology, the mentors who have influenced his clinical and academic journey, and the innovations he believes are set to transform patient care. From advances in immunotherapy and islet transplantation to the evolving landscape of diabetes treatment, Simon shares his perspectives on the opportunities ahead for the specialty.
We are delighted to announce Dr Jonathan Mertens as a touchENDOCRINOLOGY Future Leader 2026, recognized for his emerging contributions to diabetes, metabolic health and translational endocrinology research. Dr Jonathan Mertens is an endocrinologist and researcher at Antwerp University Hospital and the ...
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
In a cross-sectional study of 6,996 patients with type 2 diabetes published in Endocrine, elevated serum uric acid was associated with higher odds of prevalent diabetic retinopathy (DR) among those diagnosed before 65 years of age, but not among those diagnosed at 65 years or older.1
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
